Maharashtra FDA Uncovers Extreme Markups on Medical Devices, Seeks Price Caps

The issue came to light when Tukaram Mundhe, the Commissioner of Maharashtra's Food and Drug Administration, began scrutinizing the pricing of medical devices in private hospitals. Mundhe had previously focused on food sector regulation, but shifted his attention to healthcare after noticing unusual billing patterns.

By comparing procurement costs with the maximum retail prices charged to patients, the FDA uncovered dramatic price differences. The investigation initially centered on everyday medical consumables, which are essential for patient care but rarely questioned by those paying the bills.

On September 16, 2026, the findings were shared publicly. The FDA revealed that IV sets purchased for just Rs 11 were being billed to patients at Rs 325 in some private hospitals, representing a markup of over 2,800 percent, as noted by Indian Express. Similar price inflation was observed with other items, such as syringes, which were bought for Rs 7 and sold at Rs 57.

The same day, Mundhe highlighted the issue on social media, emphasizing that the most expensive part of a hospital bill can sometimes be the consumables, not the treatment itself, according to India News. He described this as a financial burden on patients and called for urgent government action.

The FDA then reached out to the National Pharmaceutical Pricing Authority, seeking formal guidelines and price caps to regulate the gap between procurement costs and retail prices. The Hindu reported that the FDA's recommendation aimed to increase transparency and monitoring of pricing practices.

Media coverage quickly spread, with several outlets reporting on the scale of the markups and the growing demand for intervention. The issue reignited debate over the lack of regulation in India's private healthcare sector and the need to protect consumers from predatory pricing.

At present, the Maharashtra FDA has made its recommendations to national authorities and is awaiting a response. The agency is pushing for price caps on medical devices, hoping this will force hospitals to justify their billing and reduce the burden on patients.

The story has prompted renewed calls for transparency in how hospitals price and bill for consumables. The next steps depend on whether the NPPA and central government act on the FDA's requests for intervention.

The key question is whether the National Pharmaceutical Pricing Authority will introduce formal price caps or other regulatory measures in response to the FDA's findings. Patients, hospitals, and regulators across India are watching closely, as any action could set a precedent for the entire healthcare sector.